Literature DB >> 30622144

Fluorescent labeling of CRISPR/Cas9 RNP for gene knockout in HSPCs and iPSCs reveals an essential role for GADD45b in stress response.

Masoud Nasri1, Perihan Mir1,2, Benjamin Dannenmann1, Diana Amend1, Tessa Skroblyn1,3, Yun Xu1, Klaus Schulze-Osthoff2,4, Maksim Klimiankou1, Karl Welte1,5, Julia Skokowa1,2.   

Abstract

CRISPR/Cas9-mediated gene editing of stem cells and primary cell types has several limitations for clinical applications. The direct delivery of ribonucleoprotein (RNP) complexes consisting of Cas9 nuclease and guide RNA (gRNA) has improved DNA- and virus-free gene modifications, but it does not enable the essential enrichment of the gene-edited cells. Here, we established a protocol for the fluorescent labeling and delivery of CRISPR/Cas9-gRNA RNP in primary human hematopoietic stem and progenitor cells (HSPCs) and induced pluripotent stem cells (iPSCs). As a proof of principle for genes with low-abundance transcripts and context-dependent inducible expression, we successfully deleted growth arrest and DNA-damage-inducible β (GADD45B). We found that GADD45B is indispensable for DNA damage protection and survival in stem cells. Thus, we describe an easy and efficient protocol of DNA-free gene editing of hard-to-target transcripts and enrichment of gene-modified cells that are generally difficult to transfect.
© 2019 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30622144      PMCID: PMC6325296          DOI: 10.1182/bloodadvances.2017015511

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  33 in total

1.  CRISPR gene-editing tested in a person for the first time.

Authors:  David Cyranoski
Journal:  Nature       Date:  2016-11-24       Impact factor: 49.962

2.  CRISPR/Cas9-mediated somatic and germline gene correction to restore hemostasis in hemophilia B mice.

Authors:  Cong Huai; Chenqiang Jia; Ruilin Sun; Peipei Xu; Taishan Min; Qihan Wang; Chengde Zheng; Hongyan Chen; Daru Lu
Journal:  Hum Genet       Date:  2017-05-15       Impact factor: 4.132

3.  Hematopoietic cells from Gadd45a- and Gadd45b-deficient mice are sensitized to genotoxic-stress-induced apoptosis.

Authors:  Mamta Gupta; Shiv K Gupta; Arthur G Balliet; Mary Christine Hollander; Albert J Fornace; Barbara Hoffman; Dan A Liebermann
Journal:  Oncogene       Date:  2005-11-03       Impact factor: 9.867

4.  Highly Efficient Genome Editing of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9.

Authors:  Michael C Gundry; Lorenzo Brunetti; Angelique Lin; Allison E Mayle; Ayumi Kitano; Dimitrios Wagner; Joanne I Hsu; Kevin A Hoegenauer; Cliona M Rooney; Margaret A Goodell; Daisuke Nakada
Journal:  Cell Rep       Date:  2016-10-25       Impact factor: 9.423

5.  CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells.

Authors:  Levi J Rupp; Kathrin Schumann; Kole T Roybal; Rachel E Gate; Chun J Ye; Wendell A Lim; Alexander Marson
Journal:  Sci Rep       Date:  2017-04-07       Impact factor: 4.379

6.  Gadd45b deficiency promotes premature senescence and skin aging.

Authors:  Andrew Magimaidas; Priyanka Madireddi; Silvia Maifrede; Kaushiki Mukherjee; Barbara Hoffman; Dan A Liebermann
Journal:  Oncotarget       Date:  2016-05-10

7.  A versatile system for rapid multiplex genome-edited CAR T cell generation.

Authors:  Jiangtao Ren; Xuhua Zhang; Xiaojun Liu; Chongyun Fang; Shuguang Jiang; Carl H June; Yangbing Zhao
Journal:  Oncotarget       Date:  2017-03-07

8.  Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes.

Authors:  Brett T Staahl; Madhurima Benekareddy; Claire Coulon-Bainier; Ashwin A Banfal; Stephen N Floor; Jennifer K Sabo; Cole Urnes; Gabriela Acevedo Munares; Anirvan Ghosh; Jennifer A Doudna
Journal:  Nat Biotechnol       Date:  2017-02-13       Impact factor: 54.908

9.  Reprogramming metabolic pathways in vivo with CRISPR/Cas9 genome editing to treat hereditary tyrosinaemia.

Authors:  Francis P Pankowicz; Mercedes Barzi; Xavier Legras; Leroy Hubert; Tian Mi; Julie A Tomolonis; Milan Ravishankar; Qin Sun; Diane Yang; Malgorzata Borowiak; Pavel Sumazin; Sarah H Elsea; Beatrice Bissig-Choisat; Karl-Dimiter Bissig
Journal:  Nat Commun       Date:  2016-08-30       Impact factor: 14.919

10.  Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo.

Authors:  Hao Yin; Chun-Qing Song; Joseph R Dorkin; Lihua J Zhu; Yingxiang Li; Qiongqiong Wu; Angela Park; Junghoon Yang; Sneha Suresh; Aizhan Bizhanova; Ankit Gupta; Mehmet F Bolukbasi; Stephen Walsh; Roman L Bogorad; Guangping Gao; Zhiping Weng; Yizhou Dong; Victor Koteliansky; Scot A Wolfe; Robert Langer; Wen Xue; Daniel G Anderson
Journal:  Nat Biotechnol       Date:  2016-02-01       Impact factor: 54.908

View more
  3 in total

1.  Prostaglandin E2 Enhances Aged Hematopoietic Stem Cell Function.

Authors:  Andrea M Patterson; P Artur Plett; Carol H Sampson; Edward Simpson; Yunlong Liu; Louis M Pelus; Christie M Orschell
Journal:  Stem Cell Rev Rep       Date:  2021-05-11       Impact factor: 5.739

2.  CRISPR/Cas9-mediated ELANE knockout enables neutrophilic maturation of primary hematopoietic stem and progenitor cells and induced pluripotent stem cells of severe congenital neutropenia patients.

Authors:  Masoud Nasri; Malte Ritter; Perihan Mir; Benjamin Dannenmann; Narges Aghaallaei; Diana Amend; Vahagn Makaryan; Yun Xu; Breanna Fletcher; Regine Bernhard; Ingeborg Steiert; Karin Hahnel; Jürgen Berger; Iris Koch; Brigitte Sailer; Katharina Hipp; Cornelia Zeidler; Maksim Klimiankou; Baubak Bajoghli; David C Dale; Karl Welte; Julia Skokowa
Journal:  Haematologica       Date:  2019-06-27       Impact factor: 9.941

3.  Improved CRISPR/Cas9 gene editing in primary human myoblasts using low confluency cultures on Matrigel.

Authors:  Hayley Goullée; Rhonda L Taylor; Alistair R R Forrest; Nigel G Laing; Gianina Ravenscroft; Joshua S Clayton
Journal:  Skelet Muscle       Date:  2021-09-22       Impact factor: 4.912

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.